Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs D Wave Quantum Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while D Wave Quantum Inc trades at $19.91 (market cap $7.44B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.4× D Wave Quantum Inc's market cap, and D Wave Quantum Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | QBTS | |
|---|---|---|
Market Cap | $39.89B | $7.44B |
Sector | Health | Technology |
52-Week High | $491.22 | $44.78 |
52-Week Low | $278.09 | $12.98 |
Enterprise Value | $38.15B | $6.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
D-Wave Quantum (QBTS) trades at $20.08, down 5.1% today amid bearish technical signals. The stock shows extreme valuation metrics with P/S of 551.27 and negative profitability, though analyst consensus remains unanimously bullish with a $39.86 price target representing 99% upside. Recent IDC MarketScape recognition and government grants highlight technological progress, but substantial cash burn and negative margins pose fundamental challenges.
While analyst optimism and quantum computing's long-term potential offer speculative appeal, QBTS faces significant execution risks with negative earnings, high cash burn, and competitive threats. The stock's current technical weakness near key support at $20 suggests near-term pressure, making it suitable only for risk-tolerant investors betting on quantum commercialization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
